BridgeBio Oncology Therapeutics, Inc. (BBOT) stock
BBOTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.80−0.14 (-6.96%)
Close on Nov 18, 2026Market cap $144.72MP/E –Yield –
BridgeBio Oncology Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
BridgeBio Oncology Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$151.56M. For fiscal 2025 it was -$114.50M.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$114.50M | – |
| FY2024 | Dec 31, 2024 | -$55.08M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$44.41M | – |
| Q1 FY2026 | Mar 31, 2026 | -$35.94M | – |
| Q4 FY2025 | Dec 31, 2025 | -$42.31M | – |
| Q3 FY2025 | Sep 30, 2025 | -$28.91M | – |
| Q2 FY2025 | Jun 30, 2025 | -$23.52M | – |
| Q1 FY2025 | Mar 31, 2025 | -$19.76M | – |
| Q4 FY2024 | Dec 31, 2024 | -$15.05M | – |
See a number that looks wrong?